Pioglitazone alongside light therapy for adults with non-segmental vitiligo
Tests pioglitazone used with phototherapy in adults with non-segmental vitiligo.
Key facts
- Who runs it
- I.F.O. Istituti Fisioterapici Ospitalieri
- Where
- Italy2 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- “A phase 2 multi-center study investigating the efficacy, safety and tolerability of pioglitazone in adult participants with non-segmental vitiligo”
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 60 people, planned
- Started
- 9 Dec 2025
- Expected to end
- 31 Mar 2027
- Type of study
- Interventional
- Record updated
- 26 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-segmental vitiligo on the face. A first-line treatment must not have worked for them. They will take pioglitazone together with phototherapy (light treatment).
- Age
- The criteria say 18 to 65 years. The registry age fields say 18 Years to 64 Years.
- Sex
- All sexes can join.
- Disease stage
- Non-segmental vitiligo with white (depigmented) patches. Face involvement BSA ≥0.3%, T-VASI ≥3 and F-VASI ≥0.3 at screening and baseline. The face area does not include the scalp, ears, neck or lips, but includes the nose and eyelids.
- Earlier treatment
- At least one first-line treatment (for example topical corticosteroids or calcineurin inhibitors) must have failed. People must stop all other vitiligo treatments from screening until the last follow-up visit. People who have taken part in an earlier or current investigational study cannot join.
Main reasons for not taking part
- Segmental or mixed vitiligo, or ≥50% white hair (leukotrichia) on face or body.
- Pregnancy, breastfeeding, or giving birth within the past 6 months.
- Type I or II diabetes, heart failure, liver disease or kidney disease.
- Any history of cancer, including bladder cancer, or an organ transplant needing ongoing immunosuppression.
- Abnormal blood tests, such as fasting blood glucose <70 mg/dL (3.9 mmol/L) or AST or ALT >2 times the ULN.
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Subjects must meet all the following inclusion criteria at both screening and baseline to be eligible for enrollment into the study: i) Adults between 18 years and 65 years of all genders; ii) Has a clinical diagnosis of non-segmental vitiligo with depigmented areas; iii) Has a face involvement BSA ≥0.3% at screening and baseline. The face will not include the scalp, ears, neck, or surface area of the lips but will include the nose and the eyelids; iv) Has a Total Vitiligo Scoring Index (T-VASI) ≥3 at screening and baseline; v) Has a Facial Vitiligo Area Scoring Index (F-VASI) ≥0.3 at screening and baseline. vi) Previous failure of at least one first-line treatment (e.g. topical corticosteroids or calcineurin inhibitors). vii) Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study; viii) Agree to discontinue all other vitiligo treatments from screening until the final follow-up visit in accordance with the washout times reported below in Table 2. ix) Female subjects of childbearing potential (WOCBP) and at risk for pregnancy must agree to use a highly effective method of contraception (confirmed by the investigator) throughout the study and for at least 30 days after the last PGZ dose of assigned treatment and have a negative pregnancy test result on visit 1 and each 4 weeks during the entire study; x) Female subjects of non-childbearing potential must meet at least 1 of the following criteria: • Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; status may be confirmed with a serum follicle-stimulating hormone (FSH) level confirming the postmenopausal state; • Have undergone a documented hysterectomy and/or bilateral oophorectomy; • Have medically confirmed ovarian failure. • All other female subjects (including female subjects with tubal ligations) are considered childbearing potential
Who cannot take part
- Unable to consent (adults lacking capacity); ii. Participants that have a diagnosis of other types of vitiligo including segmental and mixed vitiligo; iii. Has ≥50% leukotrichia on face or body; iv. Unable to return for follow-up visits; v. Pregnant women and/or breastfeeding, or those who have recently delivered a baby within the past 6 months; vi. Has any other dermatological diseases that would interfere with vitiligo assessments; vii. History of type I or II diabetes viii. Has a transplanted organ, which requires continued immunosuppression; ix. Has a history of any oncological malignancy; x. Familiar atypical multiple mole and melanoma (FAMMM) syndrome; xi. Systemic lupus erythematosus; xii. Dermatomyositis; xiii. Genetic conditions that predispose an individual to skin cancer (Gorlin syndrome, xeroderma pigmentosum); xiv. Bloom syndrome or Cockayne syndrome; xv. Has had major surgery within 3 months before Screening OR has a major surgery planned during the study; xvi. Has hypersensitivity to the active substance or to any of the excipients; xvii. Has cardiac failure or history of cardiac failure (NYHA stages I to IV); xviii. Has current bladder cancer or a history of bladder cancer xix. Has uninvestigated macroscopic haematuria. xx. Any evidence of fluid overload xxi. Prior/Concurrent investigational clinical study experience; xxii. Enrolled in a clinical study of any other investigational drug or device; xxiii. Liver disease, or kidney disease; xxiv. Hypoglycemia as defined by fasting blood glucose <70 mg/dL assessed at a fasting study visit; xxv. ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat, if deemed necessary: xxvi. Absolute neutrophil count of <2.5 x 109/L (<2500/mm3); xxvii. Hemoglobin <10.0 g/dL or hematocrit <30%; xxviii. Platelet count below the lower limit of normal (LLN) at Screening; xxix. Absolute lymphocyte count of <0.8 x 109 /L (<800/mm3); xxx. Serum creatinine > upper limit of normal (ULN) or eGFR <60 ml/min/1.73m2 based on the age-appropriate calculation. xxxi. Enzymes aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values >2 times the ULN; xxxii. Total bilirubin 1.5 times the ULN; subjects with a history of Gilbert's syndrome may have a direct bilirubin measured and would be eligible for this study provided the direct bilirubin is ULN; xxxiii. Creatine kinase (CK) >3 times the ULN and positive urine myoglobin; xxxiv. In the opinion of the investigator, have any uncontrolled clinically significant laboratory abnormality that would affect interpretation of study data or the subject’s participation in the study. xxxv. Patients who, in the opinion of the investigator, are unable or unlikely to comply with the administration schedule and study evaluation
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The specific object of the present clinical trial is the use of a PPARγ selective activator for the treatment of vitiligo, such as non-segmental vitiligo. The selective PPARγ activator chosen is a thiazolidinediones (TZDs), the pioglitazone (PGZ) will be used simultaneously to the phototherapy treatment.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- “A phase 2 multi-center study investigating the efficacy, safety and tolerability of pioglitazone in adult participants with non-segmental vitiligo”
- Plain-language title
- Pioglitazone alongside light therapy for adults with non-segmental vitiligoGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from 2025-523266-24-00, who can take part
- Record updated
- 26 November 2025